Ongoing studies are initially evaluating the safety and feasibility of sorafenib in this setting (NCT00997022). Clearly, there is a high risk for drug-drug interactions in this

scenario, though case-reports have suggested that sorafenib is tolerated and has efficacy in patients treated for HCC recurrence after transplant.31 Finally, HCC is a heterogeneous disease at the molecular level.32, 33 Rather than approaching all HCCs as “one disease” ongoing work is aimed at understanding which patients receive a greater benefit than others. Ultimately, this may identify a predictive marker based on serum or tumor measurements that will allow us to identify which patients will benefit Pexidartinib concentration from sorafenib and allow us to individualize treatment decisions. The patient presented in the case above is

the ideal candidate Afatinib research buy to receive systemic treatment. He has well-compensated liver disease as indicated by the lack of physical signs and symptoms of liver disease and the preserved laboratory values. There is evidence of portal hypertension with moderate thrombocytopenia but no evidence of significant bleeding or iron deficiency given the relatively normal hemoglobin and mean corpuscular volume. The patient dose not require a biopsy to confirm the diagnosis given the clinical scenario of a hypervascular tumor in the setting of cirrhosis and an elevated AFP.34 The patient is beyond transplant criteria given evidence of portal vein invasion. However, even without the portal vein thrombus, the patient’s tumor volume precludes transplant size criteria. Similarly, the portal vein thrombus would preclude any survival advantage from locally ablative therapies such as RFA and TACE. This patient appears to be asymptomatic and would be staged as BCLC Stage C. As we have reviewed, there is strong clinical evidence to support the use of sorafenib in this setting to extend survival. Although this patient is Idoxuridine very similar to those enrolled in the

SHARP study and could be started at 400 mg orally twice daily, many experienced clinicians start at a dose of 200 mg orally twice a day to minimize early toxicity and increase the dose to 400 mg orally twice a day after 1 month of therapy if the patient is tolerating the drug well. Such an approach may be associated with better long term patient tolerance of the drug and improved outcomes. Alternatively, the patient could be referred for one of the many clinical trials aimed at building on sorafenib’s success in improving survival for patients with advanced HCC. Note: Sorafenib is marketed by Onyx/Bayer Pharmaceuticals as Nexavar. The medication is available only in a 200 mg strength. The Wholesale Acquisition Cost (WAC) in the United States for a 30-day supply of Nexavar 400 mg twice daily is $6,660.95.